Experience

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which Valeant issued new debt to refinance its shorter term…

Davis Polk advised the joint book-running managers and representatives of the underwriters on an SEC-registered public debt offering by Bristol-Myers Squibb Company of $750 million…

Davis Polk advised Auris Medical Holding AG on its $10 million public offering of 10,000,000 of its common shares and 10,000,000 warrants, each warrant entitling its holder to purchase 0.7…

Davis Polk advised the joint bookrunners in connection with the initial public offering by Hermes Pardini and the selling shareholder of 40,171,429 common shares for an aggregate amount of…

Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of Coherus BioSciences, Inc. The common stock is listed on the NASDAQ…

Davis Polk advised McKesson Corporation in connection with the offering of $1 billion aggregate principal amount of notes issued by Change Healthcare Holdings, LLC and Change Healthcare…

Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…

Davis Polk advised Affimed N.V. on its $18 million public offering of 10,000,000 of its common shares. The underwriters have a 30-day option to purchase an additional 1,500,000 shares. The…

Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered offering of 4,450,500 shares of common stock of Loxo Oncology, Inc. The common stock is…

Davis Polk advised the sole book-running manager and initial purchaser in connection with a Rule 144A offering by Sucampo Pharmaceuticals, Inc. of $300 million aggregate principal amount of…